KNOWLEDGE BANK

Interviews

How can bioprinting enable better drug discovery?

CEO, Axolotl Biosciences
Dr Stephanie Willerth is a biomedical engineer entrepreneur and thought leader in D bioprinting and neural tissue engineering As CEO of Axolotl Biosciences and a Full Professor at the University of Victoria she leads innovations in personalized medicine through bioink development and human tissue models Her work bridges academia and industry bringing groundbreaking research into realworld healthca...

Articles

Harnessing Artificial Intelligence

The incorporation of Artificial Intelligence AI in the discovery and development of drugs represents a significant step towards transforming drug delivery systems

Research Insights

Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans

There is growing concern that racial and ethnic minority communities around the world are experiencing a disproportionate burden of severe acute respiratory syndrome coronavirus SARSCoV infection and coronavirus disease COVID

Case Studies

Novel Vaccines - Heat Stable Anthrax Vaccine

Challenge Existing approved Anthrax vaccines are based on cellfree filtrates of disintegrated cells of Bacillus anthracis adsorbed onto an aluminiumhydrogel adjuvant A number of side effects are attributed to these vaccines including poor safety profile and a low immunogenicity necessitating repea

Techno Trends

Genentech Discovered First Alecensa® Treatment for Early-Stage Lung Cancer

Genentech has discovered the firstever Alecensa for adjuvant treatment after tumour removal in patients with anaplastic lymphoma kinase positive nonsmall cell lung cancer

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

The Rapidly Evolving Landscape of Cancer Therapeutics

Rajesh Kumar

Rajesh Kumar is an Assistant Professor of Pharmaceutical Sciences at Kerala University of Health Sciences, India. He has been teaching Diploma, Bachelor, and Doctor of Pharmacy students for several years and is actively involved in research. He has authored more than 19 papers and is a reviewer for Bentham Science Publishers. His research includes applying the principles of pharmaceutical sciences, omics technologies, computational biology, and bioinformatics in the broad areas of cancer research, ethnopharmacology, drug delivery, targeting, and formulations.

 

Seetha Harilal

Seetha Harilal is an Assistant Professor of Pharmacology at Kerala University of Health Sciences, India. She has several years of experience in teaching Diploma, Bachelor, and Doctor of Pharmacy students and is actively pursuing research. She has authored more than 22 papers and is a manuscript reviewer for Bentham Science Publishers, Frontiers in Public Health, Frontiers in Medicine, and Archives of Medical Research (Elsevier). Her research includes the diverse areas of pharmacology and therapeutics, phytopharmaceuticals, cancer research, neurological disorders, and the application of omics technologies, computational pharmacology, and bioinformatics.

 

2

Computational Approach towards Designing Potent Inhibitors for Tuberculosis

Soumyadip Das

Soumyadip Das received a BSc degree from University of Calcutta, India, in 2017 and a MSc degree from Vellore Institute of Technology, Vellore, India, in 2019. He is currently pursuing his PhD degree from Vellore Institute of Technology, Vellore, India, under the supervision of Dr. Kaushik Chanda. His research interest includes diversity-oriented synthesis, anticancer drug design, and nanocatalysis.

 

Balamurali MM

Balamurali MM, was awarded the Master’s degree in Chemistry, by Madurai Kamaraj University, Tamil Nadu, India in 1999. He persuaded his doctoral research in Photophysical Chemistry at Indian Institute of Technology Kanpur, under the supervision of Prof. Sneh Kumar Dogra. In 2005, he was awarded the CSIR research associate fellowship and continued his postdoctoral research in Prof. Raghavan Varadarajan’s group at Indian Institute of Science Bangalore.

 

Kaushik Chanda

Kaushik Chanda, obtained his MSc in Organic Chemistry from Gauhati University, Assam India in 2001. Subsequently worked as a Senior Research Fellow in ICAR-NATP funded project in St Anthonys College, Shillong, India from 2002-2005. In 2006, he moved to Taiwan for pursuing PhD in Applied Chemistry from National Chiao Tung University under the guidance of Prof Chung Ming Sun on a topic of Combinatorial Chemistry.

 

3

3D Printing

Stéphane Roulon

Stéphane Roulon is a pharmaceutical entrepreneur with over ten years of experience in developing 3D printing technologies for drug manufacturing. He is the CEO of MB Therapeutics, a pharmaceutical establishment specializing in personalized medicines produced using advanced 3D printing solutions to support the future of precision medicine.

4

Mussel-inspired Bio-adhesives

Amisha Raikar

Amisha Raikar is a highly motivated individual with a strong educational background in the field of pharmaceutics. She completed her Bachelor of Pharmacy (B-Pharm) from Goa University in 2022, which laid the foundation for her journey into the pharmaceutical industry. Building upon her undergraduate degree, Amisha decided to pursue Master of Pharmacy (M-Pharm) in pharmaceutical science and formulation development. Recognising the importance of expanding her skill set beyond the technical aspects of pharmaceuticals, she embarked on a Postgraduate Diploma in International Business Management from the Indira Gandhi National Open University (IGNOU). Amisha's passion for learning and her desire to contribute to the field of pharmaceuticals has fueled her interest in pursuing a Ph.D. With her strong educational background, practical experience, and an eagerness to pursue further studies, Amisha Raikar is poised to make significant contributions to the field of pharmaceuticals through her future endeavours, such as a Ph.D. program.

 

5

Futuristic Application of Human-On-A-Chip Technology

Joseph Xavier

Joseph Xavier is currently pursuing his PhD in the Division of Toxicology,SCTIMST, Trivandrum, Kerala. He is currently working on the development of multi-organ-on-a-chip for disease modelling and toxicity assessments. His work also focuses on elucidating the cellular mechanism of toxicity of nanomaterials.

 

Akhil Venugopal

Akhil Venugopal is currently working as a Junior Research Fellow in the Division of Toxicology, SCTIMST, Trivandrum. He obtained his Integrated BS-MS in Chemistry from Indian Institute of Science Education and Research (IISER), Mohali. His research work is focused on the fabrication of multi-organ micro physiological devices for pre-clinical studies.

 

Arathi Ashok

Arathi Ashok obtained her Masters in Microbiology from Amrita Vishwa Vidyapeetham, Kerala. She is currently working as a Junior Research Fellow in the Division of Toxicology, SCTIMST, Trivandrum. Her research work lies in the development of organ-on-a chip devices for toxicity assessment.

 

PV. Mohanan

PV. Mohanan, FNASc, FRSB, Scientist-G and Head of Division of Toxicology and Associate Dean (PhD program) in Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Govt. of India. He has more than 33 years of research experience in Toxicology. He is a Certified Biological Safety Specialist and has authored 233 publications and edited 6 books. He is also a Visiting Professor and Visiting Researcher at Toyo University, Japan.

 

press releasesRead more...

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Telix and Ekalia a joint venture between IBA Ion Beam Applications SA EURONEXT and Framatome today announced a collaboration to advance scalable United States US production of astatine At an alphaemitting radioisotope being investigated for targeted alpha therapy

HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases

HistoIndex a pioneer in AIdriven digital pathology for fibrotic diseases and the Agency for Science Technology and Research ASTAR Singapores lead public sector RD agency have signed a Memorandum of Understanding MoU to collaborate on the preclinical evaluation

Cotecna Group Acquires Energon Labs

Cotecna a leading provider of Testing Inspection and Certification TIC services today announced the acquisition of Energon Labs a cGMPcompliant USFDAinspected ISO and ISO certified analytical testing laboratory based in Hyderabad India

Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release

Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...

Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus

Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...

EventsRead more...

21 - 23

Oct 2026

21 - 22

Oct 2026

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

PM& AC 2026

Novotel Hyderabad Convention C...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

LATEST NEWSRead more...

UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis

UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies

Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ

Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals

Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours

Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...

Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases

Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...

Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors

Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...